Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Doxorubicin-Induced Cardiomyopathy
NCT06103279Phase 3Unknown
- Sponsor
- Ain Shams University
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of empagliflozin in doxorubicin-induced cardiomyopathy, sponsored by Ain Shams University. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
doxorubicin-induced cardiomyopathy
Beyond the preview
Go deeper on NCT06103279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103279.